The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.60
Bid: 19.40
Ask: 19.70
Change: 0.19 (0.98%)
Spread: 0.30 (1.546%)
Open: 19.42
High: 19.60
Low: 19.42
Prev. Close: 19.41
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Nanoco and Merck Sign Agreement

1 Aug 2016 07:00

RNS Number : 7626F
Nanoco Group PLC
01 August 2016
 

For immediate release

1 August 2016

 

 

 

 

NANOCO GROUP PLC

("Nanoco" or the "Company")

 

 

Nanoco and Merck Sign Agreement on

Eco-Friendly Quantum Materials for Displays

 

 

· Cadmium-free quantum dots enable ultra-bright displays with a substantially extended colour range

· Nanoco enters into a non-exclusive licence agreement with Merck, which will market Nanoco's material to its broad customer base in the display industry

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, and Merck, a leading science and technology company, today announced the signing of a worldwide material supply and licensing agreement. The licence allows Merck to immediately start marketing Nanoco's cadmium-free quantum dots and to ultimately establish its own production facility to meet growing market demand.

"The agreement is in line with Merck's strategy to sustainably secure its position as the global market and technology leader in display materials. With cadmium-free quantum dots a remarkable increase in the colour range and a significant reduction in power consumption can be achieved. These cadmium-free quantum dots are eco-friendly and also complement our product portfolio for the display industry," said Walter Galinat, member of the Merck Executive Board and CEO of Performance Materials. "The licence agreement with Nanoco will strengthen our position in quantum materials research, for which we laid the foundations by acquiring Qlight Nanotech of Israel last year."

The financial details of the agreement are not being disclosed, but Nanoco will receive a licence fee and royalties on Merck's sales of the Nanoco cadmium-free quantum dots Merck manufactures. In line with Nanoco's commercialisation strategy in the display market, this agreement is non-exclusive. Merck will begin marketing Nanoco's technology in the near term by selling cadmium-free quantum dots manufactured at Nanoco's expanded production plant in Runcorn, UK. The licence allows Merck to establish its own production facility for cadmium-free quantum dots in line with global market demand at a later point in time. Michael Edelman, Nanoco's Chief Executive Officer, added: "This agreement with Merck is another major endorsement of the world-class quality of our cadmium free quantum dot technology. We are convinced that Merck can leverage its position in the display industry with these innovative materials."

Advantages of quantum materials

Quantum materials offer a substantial additional benefit when they are used as color converters in the light source of liquid crystal displays. In conventional displays, the colors blue, green, and red are filtered out of the original white light of the LED light source. A great deal of light is lost in this process. Because a blue LED in combination with red and green quantum materials only generates the blue, green and red light that is perfectly transmitted through the filters, there is much less absorption. This increases the display's brightness, reduces electricity consumption and leads to much purer and potentially stronger colors.

 

This announcement contains inside information.

 

For further information, please contact:

 

Nanoco

Tel: +44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

David Blain, Chief Financial Officer

Caroline Watson, Investor Relations Manager

cwatson@nanocotechnologies.com

 

Tel: + 44 (0) 7799 897357

Canaccord Genuity - Joint Broker

Tel: +44 (0) 20 7523 8000

Simon Bridges

Cameron Duncan

Richard Andrews

Liberum - Joint Broker

Tel: +44 (0) 20 3100 2000

Neil Patel

Richard Bootle

Steven Tredget

Buchanan

Tel: +44 (0) 20 7466 5000

Mark Court / Sophie Cowles / Stephanie Watson

 

 

 

Notes for editors:

 

About Nanoco Group plc

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nanomaterials for use in multiple applications including LC displays, lighting, solar cells and bio-imaging. In the display market, Nanoco has non-exclusive manufacturing and marketing licensing agreements with The Dow Chemical Company and Taiwan's Wah Hong Industrial Corporation. Nanoco also has a strategy of direct sales in display and in its other target markets, including lighting.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Greater China. Its technology is protected worldwide by a large and growing patent estate.

 

Nanoco is listed on the main market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

 

 

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRKMGFNGMFGVZZ
Date   Source Headline
25th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
24th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
23rd Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
22nd Apr 20244:06 pmRNSTR-1: Notification of Major Holdings
22nd Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20243:02 pmRNSExercise of Deferred Bonus Options
18th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
17th Apr 20241:56 pmRNSNotification of Major Holdings
17th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
16th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
15th Apr 20244:10 pmRNSDirector/PDMR Shareholding
15th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
11th Apr 20247:00 amRNSResult of Tender Offer
28th Mar 202412:52 pmRNSGeneral Meeting - Voting Results
27th Mar 20247:00 amRNSInterim Results
11th Mar 202412:47 pmRNSPosting of Circular
11th Mar 20247:00 amRNSProposed return of up to £33.0 million
8th Feb 20247:00 amRNSHalf Year Trading Update
7th Feb 202411:23 amRNSDirector Declaration
24th Jan 20247:00 amRNSReceipt of Final Litigation Proceeds
23rd Jan 20244:02 pmRNSNotification Of Transactions By PDMR
16th Jan 20243:40 pmRNSDirector/PDMR Shareholding
15th Jan 20244:35 pmRNSHolding(s) in Company
12th Jan 20249:45 amRNSJoint Development Agreement with European Customer
22nd Dec 20237:00 amRNSAppointment of Financial Adviser and Joint Broker
21st Dec 202312:00 pmRNSAppointments of Non-Executive Directors
12th Dec 20239:35 amRNSBlocklisting six-monthly return
7th Dec 20233:23 pmRNSResult of AGM
7th Dec 20237:00 amRNSAGM Statement & Trading Update
15th Nov 20237:00 amRNSFirst ever commercial production order
13th Nov 20234:28 pmRNS2023 Annual Report and Notice of AGM
7th Nov 20237:00 amRNSJoint Development Agreement with Asian Customer
2nd Nov 20232:18 pmRNSHolding(s) in Company
17th Oct 20237:00 amRNSUnaudited Preliminary Results
10th Oct 20237:00 amRNSNotice of Results
3rd Oct 20234:32 pmRNSForeign Currency Hedge of Litigation Settlement
14th Aug 20233:58 pmRNSResult of Meeting
8th Aug 20237:00 amRNSTrading Update
7th Aug 20237:00 amRNSGlass Lewis recommends to support Nanoco’s Board
2nd Aug 20237:00 amRNSHolding(s) in Company
2nd Aug 20237:00 amRNSISS recommendation to support Nanoco’s Board
1st Aug 20237:13 amRNSTotal Voting Rights
28th Jul 20235:23 pmRNSDirector/PDMR Shareholding
25th Jul 20232:55 pmRNSPublication of Shareholder Presentation
25th Jul 202312:52 pmRNSNanoco Group Plc
24th Jul 20237:00 amRNSHigh Court Confirmation of Capital Reduction
20th Jul 20237:00 amRNSNotification of Investor Presentation
18th Jul 20237:00 amRNSPosting of Circular and Notice of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.